Abstract Preparation and Submission Guidelines

This document will provide the information you need to prepare your abstract for submission to the 2024 AABB Annual Meeting.

CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract Categories and Topics</td>
<td>2</td>
</tr>
<tr>
<td>Abstract Timeline</td>
<td>3</td>
</tr>
<tr>
<td>Author(s) Responsibilities</td>
<td>3</td>
</tr>
<tr>
<td>How to Submit Your Abstract</td>
<td>4</td>
</tr>
<tr>
<td>Abstract Selection and Notification</td>
<td>7</td>
</tr>
</tbody>
</table>
Categories and Keywords

You will be asked to choose a primary category and up to five keywords. The primary category should reflect the overall topic of your abstract. Keywords should reflect other topics that are covered in your abstract submission.

**Biotherapies, Cellular Therapies, and Immunotherapies**
- Collections, Processing and Storage
- Cord blood *(including cord tissue and perinatal cells)*
- Hematopoietic Cell Therapy/
  - Transplant Immunotherapies *(includes CAR T cells)*
- Nonhematopoietic Cell Therapy
- Process Improvement
- Product Development and Manufacturing
- Quality Control/Quality Assurance
- Regenerative Medicine
- Regulations
- Somatic Cell Therapy

**Blood Center/Hospital-Based Donor Center**
- Blood Center/Donor Center Inventory Management
- Collections and Product Manufacturing
- Component Processing
- Donor Apheresis
- Donor Collections
- Donor Hemovigilance
- Donor Recruitment and Retention
- Donor Testing

**Cell Biology, Immunology and Biochemistry** *(Basic and Preclinical Research)*
- Leukocytes *(includes Experimental transplantation/immunotherapy)*
- Platelets
- Red Cells

**Education/Developing Curriculum**
- Competency Assessment Methods
- Curriculum Development, Implementation and Evaluation
- Professional Development
- Training Methods for Employees, Students, Residents and Fellows

**Immunohematology and Genetic Testing** *(red cells, leukocytes and platelets)*
- Immunohematology *(includes serology)*
- Molecular Diagnostics and Testing

**Hematology and Coagulation**
- Disorders
- Testing and Assay Development

**Information Technology and Informatics**
- Data Management and Analytics
- Electronic Health/Medical Records
- Laboratory Information Systems

**Instrumentation**

**Inventories**
- Inventory Distribution
- Inventory Management
- Inventory Storage

**Leadership**
- Marketing
- Operations
- Strategic Planning

**Management**
- Financial Management
- Laboratory Administration
- Personnel Management
- Practice Management
- Quality Management

**Patient Blood Management**

**Public Health, Policy and Ethics**

**Quality**
- Laboratory Safety
- Proficiency Testing
- Quality Assurance
- Quality Control
- Quality Management Systems
- Standards, Regulations and Accreditation

**Therapeutic Apheresis**

**Tissue Banking and Management**

**Transfusion Service**
- Evidence Based Medical Practices
- Patient Safety
- Patient Testing
- Pediatric Transfusion Clinical Medicine
- Perioperative and Anesthesia
- Recipient/Patient Hemovigilance – Noninfectious Adverse Events *(Transfusion Reactions)*
- Recipient/Patient Hemovigilance – Transfusion Transmitted Infectious Diseases
- Transfusion Practices
- Trauma and Massive Transfusion Practices
- Transfusion Service Inventory Management, Storage, and Distributions
Author(s) Responsibilities

Submission of an abstract indicates the following:

1. The author(s) has not published the data in a scientific journal; nor, has the data been accepted for publication before the AABB abstract submission closing date.

2. The author(s) has not presented the data at another national or international annual scientific meeting.

3. The accuracy of the submitted abstract is the responsibility of the author(s). Errors made on your submitted abstract are likely to appear in print.

4. Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, may jeopardize future acceptance of abstracts. Expenses associated with the submission and presentation of an abstract are the responsibility of the author/presenter. The presenter is required to attend the annual meeting during the day of presentation and must submit the applicable registration fee. If your abstract is selected for oral presentation, the presenting author will receive a complimentary registration for the day of the presentation.

5. The content of the presentation and reference materials must remain the responsibility of the author(s). A commercial supporter may help prepare the presentation, but they should not be biased to advance the proprietary interest of the sponsor.
How to Submit Your Abstract

All abstracts should be as informative as possible and follow the guidelines below. (Abstracts that do not follow all format guidelines will be rejected.)

1. Format

Abstracts must include the following sections:

- **Background/Case Studies** – information regarding the objectives/goals or why the study was performed.
- **Study Design/Methods** – information about the key methods utilized in the study.
- **Results/Findings** – summary of the results observed (*tables can be used, but figures cannot be used*).
- **Conclusion** – a statement of the author(s)’ conclusion supported by the stated results.

**NOTE:** Quantitative data must be included in scientific abstracts. Although data should be summarized, abstracts must include specific reference to numbers studied and statistical significance of findings. It is insufficient to state: “The results will be discussed.” or “The data will be presented.” A table or graph may be helpful in presenting data.

2. Table or Figure

- A maximum of one table or figure is accepted for each abstract.
  - Table or figure

- Naming convention for table and figure – please include the same title when you reference the figure or table in your abstract text.
  - Please use:
    - Table 1
    - Figure A

- There are three preferred formats for digital artwork submission: Encapsulated PostScript (EPS), Portable Document Format (PDF) and Tagged Image Format (TIFF). We suggest that line art be saved as EPS files. Alternately, these may be saved as PDF files at 600 dots per inch (dpi) or better at final size. Tone art, or photographic images, should be saved as TIFF files with a resolution of 300 dpi at final size. For combination figures, or artwork that contains both photographs and labeling, we recommend saving them as EPS files, or as PDF files with a resolution of 600 dpi or better at final size.

- Tables and figures can be submitted in black and white or color. Abstracts are printed in black and white in *TRANSFUSION* journal and the distinction of color in a graphic cannot be seen.
3. Additional Submission Requirements

Every effort will be made to publish the abstract exactly as submitted. Although abstracts will be typeset for electronic distribution, they will not be edited or corrected by the AABB staff except as needed to conform to publication style. Please ensure that your submission adheres to the following guidelines:

- **NEW:** LMIC (Low-and-Middle Income Countries) verification

  Please indicate if your research was conducted in a LMIC. AABB is interested in understanding the location of the research.

- **Summary of Importance to the Field**

  Submitting authors will be asked to provide a brief summary (a few sentences, maximum 500 characters) about why the abstract is novel or important to the field. Although previously published work will not be accepted, as noted in the Author(s) Responsibilities, submission of follow-up studies or reexamination of data are encouraged. In these instances, it is particularly important that the author articulates what is new or different about the research in this abstract. Please note that the abstract review and selection are blinded and references to previously published work that would identify the author(s) is grounds for rejection.

- **Commercial Bias**

  - If the presentation involves commercial products, it must be objective and rely on scientific methods.
  - Presentations must be free of commercial bias for or against any product.
  - Generic names should be used whenever possible. Abstracts submitted for promotional purposes will be rejected.

- The combined length of the abstract body, title, and table may not exceed 2,900 characters, including spaces. (Character includes all letters, numbers and punctuation.) Abstracts that exceed this character limit will be rejected by the online submission site and must be modified before the abstract can be submitted.

- Titles should be indicative of the content of the abstract. The title should be brief and must be entered in title case (first letter of every word capitalized).

- Author(s) names should have no titles or degrees listed. Author(s) institutions should be listed as precisely as possible (include city, state or country).

- Author(s) should include statistics, when it would permit a clearer interpretation of the data.

- Author(s) can include one table or one figure, which should be provided in black and white only (abstracts are printed in black and white in TRANSFUSION journal and the distinction of color in a graphic cannot be seen). Table/figure will NOT count toward the total character count.

- All units of measure must be expressed in the metric system; temperatures in Celsius.

- Generic names of drugs must be given, typed in lower case. If the proprietary name is also, given, the first letter must be capitalized.

- Unless an abbreviation is widely known and accepted (Fya, CPD, HIV), the term or phrase must be written in full the first time it appears in the abstract, followed immediately by the abbreviation in parentheses, i.e. hydroxyethyl starch (HES) or filtration leukapheresis (FL). Do not use abbreviations in the title.

- Avoid starting sentences with Arabic numbers.

- Any human subjects/animal research presented must have been approved by the appropriate agencies and have been in accordance with applicable ethical standards.
Except in rare cases, no more than ten (10) authors may be submitted and listed with each abstract. As per the rule in medical research publication, each of the authors must have contributed in at least one of three ways: 1) substantial participation in the research being reported, 2) writing of the submission, or 3) review/editing of the abstracts.

Author(s) are strongly encouraged to save an electronic or printed copy of their abstract for their records before submitting.

Avoid use of the first person in descriptions of the authors’ previous work.

- **Unacceptable:** “We previously demonstrated that…”
- **Acceptable:** “It has been shown…” or “Investigators previously demonstrated that…”

Do not include any of the following identifying information in the body or title of the abstract text, or summary of importance field.

- Name(s) of author(s)
- Names(s) of institution(s)
- Geographic locations of institutions or study site(s) (unless a significant element of the study). Some acceptable and unacceptable examples are shown below:

  - **Acceptable:** “blood components were obtained from a regional blood donor center”
  - **Acceptable:** “hospital-based blood bank”
  - **Acceptable:** “transfusion-transmitted avian influenza in southern Afghanistan”
  - **Acceptable:** “alloimmunization rates in the Yanomami of southern Venezuela”
  - **Unacceptable:** “blood components were obtained from the Pasadena County Blood Center”
  - **Unacceptable:** “blood bank of a large, tertiary care medical center in Manhattan, New York”

New for 2024, if identifying information is included, the abstract will not qualify for an oral abstract.
Abstract Selection and Notification

1. Rejection Criteria

Abstracts will be rejected by peer reviewers for any of the following reasons:

A) Insufficient data presented
B) Statistical analysis needed, but not provided
C) Stated conclusion cannot be reached from data presented
D) Information previously published or generally well known and documented
E) Format instructions not followed – no conclusion given, etc.
F) Information has limited significance or relevance and interest for national AABB meeting
G) Abstract poorly written, confusing or not clear, or contains major spelling or syntax errors
H) Commercial bias/advertising
I) Error in method or data presented
J) Other serious flaws, in the judgment of the peer reviewers

2. Decision Notification

Presenting authors will receive notification of the status of their abstract via email.

If accepted, abstracts must be presented at the AABB Annual Meeting. The presenting author must register for the meeting, prepare their poster (or oral presentation if selected) and present during their assigned session time. Failure to do so, without adequate notification and justification, may prevent the authors from submitting abstracts to future meetings. All posters must be mounted throughout the duration of the designated time and may not be removed early for any reason.